Breaking Finance News

Imprimis Pharmaceuticals (NASDAQ:IMMY) stock price target increased to $5.00, issued a ratings update today by Rodman & Renshaw

Just yesterday Imprimis Pharmaceuticals (NASDAQ:IMMY) traded 1.95% higher at $2.61. The company’s 50-day moving average is $2.79 and its 200-day average is $3.61. With the last stock price down -27.77% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Volume of trade was down over the average, with 0 shares of IMMY changing hands under the typical 55,359

Rodman & Renshaw raised the target price of Imprimis Pharmaceuticals (NASDAQ:IMMY) to $5.00 indicating a possible upside of 0.92%.

Recent Performance Chart

Imprimis Pharmaceuticals (NASDAQ:IMMY)

With a total market value of $0, Imprimis Pharmaceuticals has with a one year low of $2.22 and a one year high of $7.81 .

General Company Details For Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.